PD-1 and PD-L1 blockade in gastrointestinal malignancies

Lote, Hazel; Cafferkey, Catherine; Chau, Ian

doi:10.1016/j.ctrv.2015.09.004

Cited by 65 publications

(56 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In tumor tissues, binding of PD-1 to PD-L1 inhibits effector T-cell function, leading to suppression of the antitumor immune response and enabling neoplastic growth. Most of studies are consistent about the PD-L1 overexpression rate in upper gastrointestinal malignancies, around 40% (107). It is correlated with poorer outcome (108).…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 85%

Current therapeutic landscape for advanced gastroesophageal cancers

et al. 2018

View full text Add to dashboard Cite

Treatment of advanced gastroesophageal cancers remains challenging for clinicians, patients, and caregivers alike. Despite considerable research, the therapeutic armamentarium is restricted and hardly personalized. In the first-line setting, trastuzumab with a fluoropyrimidine and platinum agent is the standard-of-care in patients with HER2-positive tumor. For the others, a platinum-based doublet (preferably with oxaliplatin) is recommended. Three-drug cytotoxic regimens should be reserved for exceptional cases where patients have good performance status. Triple combinations produce higher toxicity and provide marginal advantage. In the second line setting, the combination of paclitaxel and ramucirumab is preferred over all others. Currently, nothing is approved in the 3 rd or later line. Nivolumab has resulted in an improved benefit in an Asian trial. Early trials of TAS-102, STAT3 inhibitors, anti-claudin 18.2 and other immune checkpoint inhibitors (alone or in combination) are ongoing. However, development of reproducible biomarkers for patient enrichment is critical for future progress.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 85%

Current therapeutic landscape for advanced gastroesophageal cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Recently, the effectiveness of new therapeutic agents, which include immune check point inhibitors, has been reported. 64) Further improvement with multidisciplinary treatment for ESCC encourages the establishment of a standardized treatment for ESCC across various countries.…”

Section: Discussionmentioning

confidence: 99%

Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan

Matsuda

Takeuchi

Kawakubo

et al. 2016

ATCS

View full text Add to dashboard Cite

Multidisciplinary treatment comprising surgery, chemotherapy, and radiotherapy for resectable esophageal squamous cell carcinoma (ESCC) is widely used with improved prognosis. Transthoracic esophagectomy (TTE) with extended lymph node (LN) dissection, known as three field LN dissection, has been recommended for ESCC using open thoracotomy or the thoracoscopic approach. The Japan Clinical Oncology Group (JCOG) trial (JCOG1409) is investigating the patients' long term survival using the thoracoscopic approach that has been shown to reduce the incidence of postoperative respiratory complication. For perioperative treatment, neoadjuvant chemotherapy using cisplatin plus 5-fluorouracil (5-FU), has been accepted as the standard of care in Japan based on the JCOG9907 trial. In Western countries, neoadjuvant chemoradiotherapy was shown to prolong overall survival for esophageal cancer, including ESCC. Although surgery has been recognized as an initial curative treatment for esophageal cancer, definitive chemoradiotherapy is an alternative treatment for patients who are unable to undergo thoracotomy or who decline to undergo surgery. This article reviews multidisciplinary treatment advances for ESCC. However, current standard treatments are country dependent and the ongoing trial may help standardize ESCC treatment across various societies.

show abstract

“…Many study reported that PD-L1 expression has been related with poor prognosis and associated with response to immunotherapy [39][40][41][42] . On the other hands, only a few studies reported that PD-L1 blockade was effective without PD-L1 expression [35] .…”

Section: Future Prospect Of Immunotherapymentioning

confidence: 99%

Management of metastatic esophagogastric junction adenocarcinoma

Toihata¹,

Imamura²,

Watanabe³

et al. 2018

JCMT

View full text Add to dashboard Cite

The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents. Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options. In this review, we summarized previous evidences of cytotoxic agents widely used worldwide, and updated recent developments of molecular targeted drugs, and immune checkpoint inhibitors.

show abstract

PD-1 and PD-L1 blockade in gastrointestinal malignancies

Cited by 65 publications

References 70 publications

Current therapeutic landscape for advanced gastroesophageal cancers

Current therapeutic landscape for advanced gastroesophageal cancers

Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan

Management of metastatic esophagogastric junction adenocarcinoma

Contact Info

Product

Resources

About